Less than three years ago, a group of Canadian scientists got together to brainstorm a better radiopharmaceutical. Radiation has a long history in cancer care, used in imaging to detect the disease as ...

Lori Lyons-Williams has always been drawn to working in oncology. For the former Allergan leader and Neumora president, there are few opportunities more impactful than treating cancer—and ...

Dosing underway in Phase 1 clinical trial for ABD-147 (DLL3-targeting radiopharmaceutical) in patients with extensive stage small cell lung cancer and large cell neuroendocrine carcinoma of the lung; ...

ABD-147 is a targeted radiopharmaceutical biologic therapy designed to deliver Actinium-225 (225Ac), a highly potent alpha-emitting radioisotope, to solid tumors expressing delta-like ligand 3 (DLL3) ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

Abdera Therapeutics Presents Initial Phase 1 Clinical Data on ABD-147, a Next-generation DLL3-targeting Radiopharmaceutical Therapy, at IASLC 2025 World Conference on Lung Cancer Data from first ...

Abdera Therapeutics Inc., a Vancouver biopharma startup specializing in the treatment of cancer with radioisotopes, has landed $142 million in Series A and B financing, just a couple of years after ...

MENLO PARK, Calif. & VANCOUVER, British Columbia--(BUSINESS WIRE)--Abdera Therapeutics Inc., a biopharmaceutical company leveraging its advanced antibody engineering ROVEr™ platform to design and ...

Data from first patient cohort provide human proof-of-concept and support continued dose escalation in patients with small cell lung cancer and large cell neuroendocrine carcinoma Pharmacokinetic, ...

Abdera Therapeutics Inc., a Vancouver biopharma startup specializing in the treatment of cancer with radioisotopes, has landed $142 million in Series A and B financing, just a couple of years after ...